Skip to main content
SpringerLink
Log in

Pharmacotherapy of anxiety disorders in German-speaking countries: current status and changes between 1994 and 2011

  • Original Paper
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

Over the past years, international treatment guidelines have been established for the treatment of anxiety disorders. Nevertheless, little is known as to whether the actual inpatient treatment follows these guidelines. The main goal of this study was to answer the question whether patients with anxiety disorder are treated according to treatment guidelines. A total of 2,573 psychiatric inpatients with the diagnosis of anxiety disorder (920 men, 1,653 women) were identified on the basis of the data of the international drug safety programme in psychiatry AMSP. Of these patients, 25.3 % presented with phobia, 26.6 % with panic disorder, 18.7 % with generalized anxiety disorder (GAD), and 29.4 % with other diagnoses of anxiety. In all of the patients, 12.7 % did not receive any psychotropic medication and 22.9 % were not treated with antidepressants. Only 59.3 % of patients with GAD, 73.9 % of patients with panic disorder, and 52.1 % of patients with phobia were treated according to diagnostic guidelines. The majority (60.3 %) of all patients received one or two psychotropic drugs, and only 3.7 % received five or more psychotropic drugs. In two groups of patients (one group with phobia and one with panic disorder), the annual prescription rate of antidepressants significantly increased over time. The prescription rate for anticonvulsants in patients with GAD increased from 0 % in 1997 to 41.7 % in 2011, and for antipsychotics, from 40.7 % in 1997 to 47.2 % in 2011. In particular, patients with GAD were commonly treated with antipsychotics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. American Psychiatric Association (1998) Practice guidelines for the treatment of patients with panic disorder. Working group on panic disorder. American Psychiatric Association. Jack Gorman

  2. American Psychiatric Association (2010) Practice guidelines for the treatment of patients with panic disorders, 2nd edn. Working group on panic disorder. American Psychiatric Association. Laura J. Fochtmann

  3. Baldwin DS, Waldman S, Allgulander C (2011) Evidence-based pharmacological treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 14(5):697–710

    Article  CAS  PubMed  Google Scholar 

  4. Bandelow B, Chouinard G, Bobes J, Ahokas A, Eggens I, Liu S et al (2010) Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. Int J Neuropsychopharmacol 13(3):305–320

    Article  CAS  PubMed  Google Scholar 

  5. Bandelow B, Sher L, Bunevicius R, Hollander E, Kasper S, Zohar J et al (2012) Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care. Int J Psychiatry Clin Pract 16(2):77–84

    Article  CAS  PubMed  Google Scholar 

  6. Bandelow B, Stein DJ, Dolberg OT, Andersen HF, Baldwin DS (2007) Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. Pharmacopsychiatry 40(4):152–156

    Article  CAS  PubMed  Google Scholar 

  7. Bandelow B, Wiltink J, Alpers G, Benecke C, Deckert J, Eckhardt-Henn A et al (2014) Deutsche S3-Leitlinie Behandlung von Angststörungen. www.awmf.org/leitlinien.html

  8. Bandelow B, Zohar J, Hollander E, Kasper S, Möller H-J, Allgulander C et al (2008) World federation of societies of biological psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders—first revision. World J Biol Psych 9(4):248–312

    Article  Google Scholar 

  9. Beck AT, Steer RA, Sanderson WC, Skeie TM (1991) Panic disorder and suicidal ideation and behavior: discrepant findings in psychiatric outpatients. Am J Psychiatry 148(9):1195–1199

    Article  CAS  PubMed  Google Scholar 

  10. Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T (2005) Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 187:352–359

    Article  PubMed  Google Scholar 

  11. Claxton AJ, Cramer J, Pierce C (2001) A systematic review of the associations between dose regimens and medication compliance. Clin Therapeutics 23(8):1296–1310

    Article  CAS  Google Scholar 

  12. Cramer JA, Mattson RH, Prevey ML, Scheyer RD, Ouellette VL (1989) How often is medication taken as prescribed? A novel assessment technique. J Am Med Assoc 261(22):3273–3277

    Article  CAS  Google Scholar 

  13. Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Möller H-J (2005) World federation of societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: acute treatment of schizophrenia. World J Biol Psychiatry 6(3):132–191

    Article  PubMed  Google Scholar 

  14. Friedman S, Jones JC, Chernen L, Barlow DH (1992) Suicidal ideation and suicide attempts among patients with panic disorder: a survey of two outpatient clinics. Am J Psychiatry 149(5):680–685

    Article  CAS  PubMed  Google Scholar 

  15. Furmark T, Appel L, Michelgård A, Wahlstedt K, Ahs F, Zancan S et al (2005) Cerebral blood flow changes after treatment of social phobia with the neurokinin-1 antagonist GR205171, citalopram, or placebo. Biol Psychiatry 58(2):132–142

    Article  CAS  PubMed  Google Scholar 

  16. Gambi F, De Berardis D, Campanella D, Carano A, Sepede G, Salini G et al (2005) Mirtazapine treatment of generalized anxiety disorder: a fixed dose, open label study. J Psychopharmacol 19(5):483–487

    Article  CAS  PubMed  Google Scholar 

  17. Grohmann R, Engel RR, Rüther E, Hippius H (2004) The AMSP drug safety program: methods and global results. Pharmacopsychiatry 37(Suppl 1):S4–S11

    PubMed  Google Scholar 

  18. Hahn A, Lanzenberger R, Wadsak W, Spindelegger C, Moser U, Mien L-K et al (2010) Escitalopram enhances the association of serotonin-1A autoreceptors to heteroreceptors in anxiety disorders. J Neurosci 30(43):14482–14489

    Article  CAS  PubMed  Google Scholar 

  19. Kasper S, Brasser M, Schweizer E, Lyndon G, Prieto R (2014) How well do randomized controlled trial data generalize to “real-world” clinical practice settings? A comparison of two generalized anxiety disorder studies. Eur Neuropsychopharmacol 24(1):125–132

    Article  CAS  PubMed  Google Scholar 

  20. Kasper S, Herman B, Nivoli G, Van Ameringen M, Petralia A, Mandel FS et al (2014) Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial. Int Clin Psychopharmacol 24(2):87–96

    Article  Google Scholar 

  21. Kasper S, Stein DJ, Loft H, Nil R (2005) Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186:222–226

    Article  PubMed  Google Scholar 

  22. Katona CL (2001) Psychotropics and drug interactions in the elderly patient. Int J Geriatr Psychiatry 16(Suppl 1):S86–S90

    Article  PubMed  Google Scholar 

  23. Klein DF (1964) Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 5:397–408

    Article  CAS  PubMed  Google Scholar 

  24. Lepola UM, Wade AG, Leinonen EV, Koponen HJ, Frazer J, Sjödin I et al (1998) A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 59(10):528–534

    Article  CAS  PubMed  Google Scholar 

  25. Mezhebovsky I, Mägi K, She F, Datto C, Eriksson H (2013) Double-blind, randomized study of extended release quetiapine fumarate (quetiapine XR) monotherapy in older patients with generalized anxiety disorder. Int J Geriatr Psychiatry 28(6):615–625

    Article  PubMed  Google Scholar 

  26. Montgomery SA, Kasper S (2012) Clinical Medicine Insights : therapeutics pharmacotherapy Update: pregabalin in the treatment of generalized anxiety disorder. Clin Med Insights Therapeutics 2:189–202

    Google Scholar 

  27. Montgomery SA, Locklear JC, Svedsäter H, Eriksson H (2014) Efficacy of once-daily extended release quetiapine fumarate in patients with different levels of severity of generalized anxiety disorder. Int Clin Psychopharmacol. http://www.ncbi.nlm.nih.gov/pubmed/24394383

  28. National Institute for Health and Clinical Excellence (2004) NICE clinical guideline, anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalised anxiety disorder) in adults in primary, secondary and community care. NHS, NICE Clinical Guieline 22

  29. National Institute for Health and Clinical Excellence (2011) NICE clinical guideline, generalized anxiety disorder and panic disorder (with or without agoraphobia) in adults. NHS, NICE Clinical Guideline 113

  30. Pollack M, Mangano R, Entsuah R, Tzanis E, Simon NM, Zhang Y (2007) A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology 194(2):233–242

    Article  CAS  PubMed  Google Scholar 

  31. Pollack MH, Lepola U, Koponen H, Simon NM, Worthington JJ, Emilien G et al (2007) A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depress Anxiety 24(1):1–14

    Article  CAS  PubMed  Google Scholar 

  32. Pollack MH, Worthington JJ, Otto MW, Maki KM, Smoller JW, Manfro GG et al (1996) Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull 32(4):667–670

    CAS  PubMed  Google Scholar 

  33. Ribeiro L, Busnello JV, Kauer-Sant’Anna M, Madruga M, Quevedo J, Busnello EA et al (2001) Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 34(10):1303–1307

    Article  CAS  PubMed  Google Scholar 

  34. Samuel M, Zimovetz EA, Gabriel Z, Beard SM (2011) Efficacy and safety of treatments for refractory generalized anxiety disorder: a systematic review. Int Clin Psychopharmacol 26(2):63–68

    Article  PubMed  Google Scholar 

  35. Sheehan DV, Svedsäter H, Locklear JC, Eriksson H (2013) Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with generalized anxiety disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study. J Affect Disord 151(3):906–913

    Article  CAS  PubMed  Google Scholar 

  36. Spindelegger C, Lanzenberger R, Wadsak W, Mien LK, Stein P, Mitterhauser M et al (2009) Influence of escitalopram treatment on 5-HT 1A receptor binding in limbic regions in patients with anxiety disorders. Mol Psychiatry 14(11):1040–1050

    Article  CAS  PubMed  Google Scholar 

  37. Stahl SM, Gergel I, Li D (2003) Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64(11):1322–1327

    Article  CAS  PubMed  Google Scholar 

  38. Vaishnavi S, Alamy S, Zhang W, Connor KM, Davidson JRT (2007) Quetiapine as monotherapy for social anxiety disorder: a placebo-controlled study. Prog Neuro Psychopharmacol Biol Psychiatry 31(7):1464–1469

    Article  CAS  Google Scholar 

  39. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T (1997) The effect of citalopram in panic disorder. Br J Psychiatry 170:549–553

    Article  CAS  PubMed  Google Scholar 

  40. Waern M, Spak F, Sundh V (2002) Suicidal ideation in a female population sample. Relationship with depression, anxiety disorder and alcohol dependence/abuse. Eur Arch Psychiatry Clin Neurosci 252(2):81–85

    Article  PubMed  Google Scholar 

  41. Weisberg RB, Beard C, Moitra E, Dyck I, Keller MB (2014) Adequacy of treatment received by primary care patients with anxiety disorders. Depress Anxiety 31(5):443–450

    Article  PubMed Central  PubMed  Google Scholar 

  42. Weissman MM, Klerman GL, Markowitz JS, Ouellette R (1989) Suicidal ideation and suicide attempts in panic disorder and attacks. N Engl J Med 321(18):1209–1214

    Article  CAS  PubMed  Google Scholar 

  43. Wensel TM, Powe KW, Cates ME (2012) Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother 46(3):424–429

    Article  PubMed  Google Scholar 

  44. Wittchen HU, Jacobi F, Rehm J, Gustavsson A, Svensson M, Jönsson B et al (2011) The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 21(9):655–679

    Article  CAS  PubMed  Google Scholar 

  45. Zitrin CM (1983) Differential treatment of phobias: use of imipramine for panic attacks. J Behav Ther Exp Psychiatry 14(1):11–18

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the AMSP Drug Safety Programme, Hannover, Germany.

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Psychiatry, Graz Medical University, Auenbruggerplatz 31, 8036, Graz, Austria

    Anna K. Holl, Martin Letmaier, Annamaria Painold & Sabrina Mörkl

  2. Department of Psychiatry, Ludwig-Maximilians-University, 80336, Munich, Germany

    Renate Grohmann

  3. Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, 30625, Hannover, Germany

    Sermin Toto

  4. Division of Biological Psychiatry, Department of Psychiatry and Psychotherapy, Medical University of Vienna, 1090, Vienna, Austria

    Siegfried Kasper

Authors
  1. Anna K. Holl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Renate Grohmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Letmaier
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Annamaria Painold
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sabrina Mörkl
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sermin Toto
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Siegfried Kasper
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Annamaria Painold.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Holl, A.K., Grohmann, R., Letmaier, M. et al. Pharmacotherapy of anxiety disorders in German-speaking countries: current status and changes between 1994 and 2011. Eur Arch Psychiatry Clin Neurosci 265, 199–208 (2015). https://doi.org/10.1007/s00406-014-0523-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-014-0523-7

Keywords

Search

Navigation